Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2013

View Archived Issues

Novel therapy discovered for X-linked adrenoleukodystrophy

Cell therapy leads to improvements in spinal cord injury patient

AstraZeneca discovers novel PET radioligands that selectively bind to H3 receptors

New MJFF grant to support development of ND-0612

Fujifilm and Dr. Reddy's cancel partnership for generic drugs in Japan

Actelion Pharmaceuticals patents novel agents for bacterial infections

New mouse model of dominant uveal coloboma presented at ARVO

Sanofi updates on phase III iniparib and otamixaban studies

Fujifilm begins phase I study of anticancer agent in Japan

GSK reports phase III data for lapatinib plus chemotherapy in gastric cancer

GlaxoSmithKline to develop and commercialize MOR-103

Lambrolizumab shows significant activity and durable response in patients with melanoma

Natrogen Therapeutics International presents in vivo results for promising novel SLE therapy

FDA grants orphan drug status to ibrutinib, diazepam auto-injector and abatacept

Merck & Co. patents new series of DGAT1 inhibitors

Novel EZH2 inhibitors presented by Constellation Pharmaceuticals

Purdue Pharma divulges novel Na(V)1.7 channel blockers

Novel GPR119 receptor agonists patented by Array BioPharma

AstraZeneca to return rights to RA candidate following phase III results

AbbVie patents new Nampt inhibitors

Autifony commences phase I study of drug for treatment of hearing loss and tinnitus

FDA grants priority review to Bristol-Myers Squibb and AstraZeneca's metreleptin

FDA clears Kinex Pharmaceuticals' IND for KX-02

La Jolla Pharmaceutical submits IND to the FDA for LJPC-501

Naurex begins phase I trial of antidepressant agent NRX-1074

Octapharma submits MAA to the EMA for human recombinant coagulation factor VIII

Zeria and Astellas set to launch functional dyspepsia treatment Acofide in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...